Skip to content
Screener

Agilon Health AGL Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Flutter Entertainment logo
Flutter EntertainmentFLUT
$3.62B+3.0%
Stifel Financial logo
Stifel FinancialSF
$2.22B+15.3%
Primo Brands logo
Primo BrandsPRMB
$366.8M-11.1%
Eagle Bancorp Montana logo
Eagle Bancorp MontanaEBMT
$28.96M+7.5%
Agilon Health logo
Agilon HealthAGL
$178.81M+4.3%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$332.46M+45.4%

Other financials

Income statement

See full
Revenue$1.5B+7.2%
Operating income$11.8M+110%
Net income$18.0M+117%
EPS (diluted)$1.04+116%

Balance sheet

See full
Cash & equivalents$178.8M+4.3%
Total debt$33.4M-19.2%
Total equity$227.5M-44.4%
Total assets$1.6B-7.1%

Cash flow

See full
Operating cash flow-$57.3M-63.3%
CapEx$3.4M+6.1%
Free cash flow-$60.7M-58.5%

Valuation

See full
Market cap$1.6B+348%
Enterprise value$1.46B+540%
P/S0.3×+0.2×

Profitability

See full
Operating margin-5.2%-0.8pp
Net margin-3.9%-0.8pp
FCF margin-1.4%

Returns & leverage

See full
Return on equity-73%+24.9pp
Debt / equity0.1×0.0×
Current ratio1.1×-0.1×

Where this comes from

Reported directly by Agilon Health in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The source filing: Agilon Health’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053355
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows from financing activities:
Proceeds from (payments for) equity issuances, net4,596(2,741)
Debt issuance costs(1,612)
Repayments of long-term debt(3,500)
Net cash provided by (used in) financing activities(516)(2,741)
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents5,098(22,444)
Cash, cash equivalents and restricted cash and equivalents, beginning of period173,713193,860
Cash, cash equivalents and restricted cash and equivalents, end of period$178,811$171,416

Item 1. Financial Statements

FAQ

What is Agilon Health's cash and cash equivalents, end of period?
Agilon Health (AGL) reported cash and cash equivalents, end of period of $178.81M in Q2 2026.
How has Agilon Health's cash and cash equivalents, end of period changed year-over-year?
Agilon Health's cash and cash equivalents, end of period increased by 4.3% year-over-year, from $171.42M to $178.81M.
What is the long-term trend for Agilon Health's cash and cash equivalents, end of period?
Over 3 years (2022 to 2025), Agilon Health's cash and cash equivalents, end of period has grown at a -30.1% compound annual growth rate (CAGR), from $507.68M to $173.71M.
What does cash and cash equivalents, end of period mean?
Cash and cash equivalents, end of period

Ask your AI about Agilon Health's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude